Chronic Venous Insufficiency
Chronic venous insufficiency (CVI) may occur following excessive clotting and inflammation
of the leg veins, a disease known as deep vein thrombosis. CVI also results from a simple
failure of the valves in leg veins to hold blood against gravity, leading to sluggish movement
of blood out of the veins, resulting in swollen legs.
Checklist for Chronic Venous
Insufficiency
What are the symptoms of chronic venous insufficiency? CVI may
cause feet and calves to become swollen, often accompanied by a dull ache made worse with
prolonged standing. If CVI is allowed to progress, the skin tends to darken and ulcers may
occur. CVI often causes varicose veins.
How is it treated? It is typically advised to elevate the legs
frequently, avoid prolonged standing or sitting, and wear graduated compression stockings with
supportive shoes. Any ulcers that develop are treated with compressive bandages that contain
antibiotic solutions. Recurrent ulceration may be
surgically treated with skin grafts and repair or bypass of the affected veins.
Lifestyle changes that may be helpful: People affected by
chronic venous insufficiency should not sit or stand for long periods of time. When sitting,
they should elevate their legs. Walking helps move blood out of the veins. Wearing
tight-fitting compression stockings available from pharmacies further supports the veins.
Nutritional supplements that may be helpful: Flavonoids promote venous strength and integrity. Most trials of
flavonoids in patients with CVI have used a type of flavonoid called hydroxyethylrutoside
(HR), which is derived from rutin. These double-blind and other controlled trials have
consistently shown a beneficial effect of HR in clearing leg swelling and other signs of
CVI.1 2 3 Positive results from a double-blind trial have
been obtained using 500 mg of HR taken twice per day for 12 weeks.4 In this trial,
the preparation was found to add further benefit to that provided by compression stockings
commonly used to treat CVI. Similar results were obtained in another controlled
trial.5 It is unclear whether other flavonoids are as effective as HR for CVI. HR
has also been used successfully as a topical preparation for the treatment of
CVI.6
Proanthocyanidins (OPCs), a group of flavonoids
found in pine bark, grape seed, grape skin, bilberry, cranberry, black
currant, green tea, black
tea, and other plants, have also been shown to strengthen capillaries in double-blind
research using as little as two 50 mg tablets per day.7 In a double-blind trial
using a total of 150 mg OPCs per day, French researchers reported reduced symptoms for women
with CVI.8 In another French double-blind trial, supplementation with 100 mg taken
three times per day resulted in benefits within four weeks.9
Are there any side effects or interactions? Refer to the individual supplement for
information about any side effects or interactions.
Herbs that may be helpful: According to an extensive overview
of clinical trials, standardized horse chestnut seed
extract, which contains the active compound aescin, has been shown to be effective in
double-blind and other controlled research, supporting the traditional use of horse chestnut
for venous problems.10 In these trials, capsules of horse chestnut extract
containing 50 mg of aescin were given two to three times daily for CVI. The positive effect
results in part from horse chestnut’s ability to strengthen capillaries, which leads to
a reduction in swelling.11
Another traditional remedy for CVI is butcher’s
broom. One double-blind trial used a combination of butcher’s broom, the flavonoid hesperidin, and vitamin
C. This was found to be better than a placebo for treating CVI.12 In a
comparison study, a product combining butcher’s broom extract, the flavonoid hesperidin,
and vitamin C was more effective than a synthetic flavonoid product for treating
CVI.13 Clinical trials have used one capsule, containing standardized extracts
providing 15 to 30 mg of ruscogenins, three times each day. The amount of butcher’s
broom extract used in these trials is 150 mg two times per day. Other sources recommend
standardized extracts providing 15 to 30 mg of ruscogenins, given three times each day.
Gotu kola extracts, standardized to triterpenoid
content, have been found successful in small preliminary trials to treat CVI.14 The
amount of extract used in these trials ranged from 60 to 120 mg per day.
A double-blind trial demonstrated that red vine leaf extract is effective at relieving the
symptoms and swelling associated with CVI.15 One group of participants took either
360 mg or 720 mg per day of a standardized extract for 12 weeks, and another group took a
placebo. At the end of the treatment period, those who had taken the herb experienced
significant improvement in symptoms of leg heaviness, tension sensation, tingling, and pain
compared with those who had taken the placebo. Objective measurements of leg swelling were
also significantly improved in the red vine group compared to the placebo group.
Are there any side effects or interactions? Refer to the individual herb for
information about any side effects or interactions.
References:
1. Rehn D, Brunnauer H, Diebschlag W, Lehmacher W. Investigation of the
therapeutic equivalence of different galenical preparations of O-(s-hydroxyethyl)-rutosides
following multiple dose per oral administration. Arzneimittelforschung
1996;46:488–92.
2. Bergqvist D, Hallbook T, Lindblad B, Lindhagen A. A double-blind trial
of O-(s-hydroxyethyl)-rutoside in patients with chronic venous insufficiency. Vasa
1981;10:253–60.
3. Poynard T, Valterio C. Meta-analysis of hydroxyethylrutosides in the
treatment of chronic venous insufficiency. Vasa 1994;23:244–50.
4. Unkauf M, Rehn D, Klinger J, et al. Investigation of the efficacy of
oxerutins compared to placebo in patients with chronic venous insufficiency treated with
compression stockings. Arzneimittelforschung 1996;46:478–82.
5. Neumann HA, van den Broek MJ. A comparative clinical trial of
graduated compression stockings and O-(beta-hydroxyethyl)-rutosides (HR) in the treatment of
patients with chronic venous insufficiency. Z Lymphol 1995;19:8–11.
6. Frick RW. Three treatments for chronic venous insufficiency: escin,
hydroxyethylrutoside, and Daflon. Angiology 2000;51:197–205 [review].
7. Dartenuc JY, Marache P, Choussat H. Resistance Capillaire en Geriatrie
Etude d’un Microangioprotecteur. Bordeax Médical 1980;13:903–7 [in
French].
8. Delacroix P. Etude en Double Avengle de l’Endotelon dans
l’Insuffisance Veineuse Chronique. Therapeutique, la Revue de Medicine
1981;Sept 27–28:1793–1802 [in French].
9. Thebaut JF, Thebaut P, Vin F. Study of Endotelon in functional
manifestations of peripheral venous insufficiency. Gazette Medicale
1985;92:96–100 [in French].
10. Pittler MH, Ernst E. Horse-chestnut seed extract for chronic venous
insufficiency: a criteria-based systematic review. Arch Dermatol
1998;134:1356–60.
11. Bisler H, Pfeifer R, Klüken N, Pauschinger P. Effects of
horse-chestnut seed extract on transcapillary filtration in chronic venous insufficiency.
Deutche Med Wochenschr 1986;111:1321–9 [in German].
12. Cappelli R, Nicora M, Di Perri T. Use of extract of Ruscus aculeatus
in venous disease in the lower limbs. Drugs Exp Clin Res 1988;14:277–83.
13. Beltramino R, Penenory A, Buceta AM. An open-label, randomized
multicenter study comparing the efficacy and safety of Cyclo 3 Fort® versus hydroxyethyl
rutoside in chronic venous lymphatic insufficiency. Angiology
2000;51:535–44.
14. Brinkhaus B, Linder M, Schuppan D, Hahn EG. Chemical, pharmacological
and clinical profile of the East Asian medical plant Centella asiatica. Phytomedicine
2000;7:427–48.
15. Kiesewetter H, Koscielny J, Kalus U, et al. Efficacy of orally
administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic
venous insufficiency (stages I-II). A randomized, double-blind, placebo-controlled trial.
Arzneimittelforschung 2000;50:109–17.
Copyright © 2002 Healthnotes, Inc. All rights reserved.
www.healthnotes.com
Learn more about Healthnotes, the company.
Learn more about the authors of Healthnotes.
The information presented in Healthnotes is for informational
purposes only. It is based on scientific studies (human, animal, or in vitro),
clinical experience, or traditional usage as cited in each article. The results reported may
not necessarily occur in all individuals. For many of the conditions discussed, treatment with
prescription or over-the-counter medication is also available. Consult your doctor,
practitioner, and/or pharmacist for any health problem and before using any supplements or
before making any changes in prescribed medications. Information expires December 2003.
|